This content is in French.
A heterogeneous cancer, evolving management
16 octobre 2025
By Ana Espino | Published on October 16, 2025 | 2 min readMetastatic breast cancer (MBC) remains an incurable disease with highly heterogeneous clinical forms. Despite recent advances, standard treatments—hormone therapy, chemotherapy, and immunotherapy—have limitations in the face of secondary resistance, genetic variability of tumors, and the progressive exhaustion of therapeutic options. In thi
Metastatic breast cancer (MBC) remains an incurable disease with highly heterogeneous clinical forms. Despite recent advances, standard treatments—hormone therapy, chemotherapy, and immunotherapy—have limitations in the face of secondary resistance, genetic variability of tumors, and the progressive exhaustion of therapeutic options. In this context, targeted therapy based on molecular alterations is emerging as a promising strategy, offering a more personalized, more effective, and better-tolerated approach to treatment.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Abdullah, H. M. A., et al. (2025). Precision therapy in metastatic breast cancer: the current landscape of molecular alteration-based therapies. Translational breast cancer research : a journal focusing on translational research in breast cancer, 6, 24.
View the source
